Establishing a Regulatory Framework for Innovative Targeted Therapies

An update to the FDA regulatory database for Gleevec (imatinib mesylate), a targeted therapy from Novartis (NVS), has been confirmed. This update is significant as it modernizes the safety profile accumulated over decades in the global market. Notably, on January 2026, information on drug interactions with methotrexate and clinical pharmacology was updated, demonstrating ongoing management. This underscores Novartis's regulatory capabilities in protecting the safety of patients who often require long-term treatment and providing accurate guidelines to healthcare professionals.

Transforming the Paradigm of Leukemia Treatment and Historical Background

Gleevec is historically recognized as the first Bcr-Abl tyrosine kinase inhibitor (TKI) that inhibits specific proteins in cancer cells. Following the approval of the capsule formulation (NDA 021335) on May 10, 2001, a tablet formulation (NDA 021588) with improved convenience and formulation stability was additionally approved on April 18, 2003. This drug has elevated the five-year survival rate of patients with chronic myelogenous leukemia (CML) from less than 30% to over 90%, solidifying its status as a standard of care. This paradigm-shifting innovation was made possible through close collaboration with regulatory agencies and formulation improvement research, ultimately reaching patients.

Market Dominance and Market Restructuring After Patent Expiration

Gleevec expanded its indications to include gastrointestinal stromal tumors (GIST), achieving peak annual global sales of USD 4.7 billion in 2015. However, with the expiration of the U.S. market patent in 2016, a surge of generic drugs entered the market, leading to a sharp decline in sales. In response, Novartis recorded cumulative sales of approximately USD 39.7 billion before and after patent expiration, completing its role as a major cash cow and securing resources for reinvestment in next-generation pipeline development. Maintaining a certain level of market share even after patent expiration can be attributed to the brand's established trust and thorough regulatory data updates.

Competition with Second-Generation Treatments and Future Directions for the Anti-Cancer Market

The market is currently witnessing intense competition for leadership among second-generation TKIs such as Sprycel (dasatinib) from BMS and Tasigna (nilotinib), Novartis's own successor drug. These subsequent drugs offer alternatives for patients who exhibit resistance to or experience adverse effects from Gleevec, inducing molecular response more rapidly. However, Gleevec still holds a strong position as a first-line treatment due to its accumulated clinical data and cost-effectiveness. Ultimately, in the chronic leukemia treatment market, the regulatory standards and clinical indicators established by Gleevec serve as a solid benchmark for future innovative drugs.